DEVICE USER FEES FOR DEFICIT REDUCTION PROPOSED BY HOUSE BUDGET CMTE., SENATE BUDGET PROPOSAL WOULD "FULLY FUND" FDA BUT ELIMINATE MONEY FOR CAMPUS
This article was originally published in The Gray Sheet
Device industry user fees for deficit reduction are called for in a recent document on the fiscal 1996 budget resolution drafted by the majority staff of the House Budget Committee.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.